))
“Better to Have Choices”: How New Data Transform EGFR-Mutated NSCLC Care
Manage episode 409520061 series 3560609
Content provided by Jacqueline Stone and Oncololgy News Central. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Jacqueline Stone and Oncololgy News Central or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Given recent data, how should oncologists choose a tyrosine kinase inhibitor (TKI) in patients with EGFR-mutated non-small cell lung cancer (NSCLC), and when should chemotherapy be introduced? “It’s better to have choices than not,” explains Paul Bunn, MD, the Dudley Chair in Cancer Research at the University of Colorado in Aurora. Dr. Bunn discusses how recent trials influence treatment decisions in NSCLC with Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at Cedars-Sinai Cancer Center in Los Angeles. Dr. Bunn stresses why molecular testing is so crucial and previews what additional findings are likely to further change practice in patients with EGFR-mutated NSCLC.
120 episodes
Share
